东宝生物(300239) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥188,836,626.25, representing a decrease of 11.75% compared to the same period last year[2]. - Net profit attributable to shareholders was ¥14,931,897.78, down 50.65% year-on-year[2]. - The net profit after deducting non-recurring gains and losses was ¥13,134,578.07, a decline of 51.57% compared to the previous year[2]. - The basic earnings per share (EPS) was ¥0.0252, reflecting a decrease of 50.59% year-on-year[2]. - Total operating revenue for the period was CNY 633,112,065.92, a decrease of 13.8% compared to CNY 734,671,103.09 in the previous period[17]. - Net profit for the period was CNY 71,535,188.56, a decline of 29.7% from CNY 101,932,609.79 in the previous period[18]. - Earnings per share (EPS) for the period was CNY 0.1116, compared to CNY 0.1605 in the previous period[19]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥29,272,022.08, down 77.53% compared to the same period last year[2]. - Net cash flow from operating activities dropped by 77.53% to 29,272,022.08, due to lower cash received from sales compared to the previous year[9]. - The net cash flow from investing activities decreased by 76.87% to -134,567,469.44, primarily due to cash payments for fixed assets and the acquisition of minority interests[9]. - The cash flow from financing activities showed a net outflow of -¥18,959,353.05, a stark contrast to a net inflow of ¥320,156,942.98 in Q3 2023[21]. - The total cash inflow from investing activities was ¥661,893,506.91, significantly higher than ¥190,042.99 in the same period last year[21]. - The company reported a total cash outflow from operating activities of ¥443,490,174.55, compared to ¥404,134,312.87 in the previous year, reflecting increased operational expenses[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,717,616,443.48, a decrease of 0.89% from the end of the previous year[2]. - The total current liabilities increased to ¥442.28 million from ¥300.94 million, indicating a rise of approximately 47%[15]. - The company's long-term borrowings and bonds payable amounted to ¥474.26 million, slightly down from ¥476.26 million[15]. - The company's total liabilities increased to CNY 996,926,079.56, up from CNY 848,818,198.38 in the previous period[18]. - The total assets decreased slightly to ¥2.72 billion from ¥2.74 billion, reflecting a decline of about 0.9%[15]. Inventory and Receivables - Inventory increased by 35.01% to ¥380,081,920.53 due to market fluctuations and reduced product sales[6]. - Accounts receivable increased to ¥180.80 million from ¥162.03 million, showing a growth of about 11.6%[14]. - Inventory rose significantly to ¥380.08 million from ¥281.53 million, marking an increase of approximately 35%[14]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,564, with the largest shareholder holding 21.18% of the shares[10]. - The company reported a total of 69,673,459 shares in lock-up status, with a significant portion released in June 2024[11]. Other Financial Metrics - The weighted average return on net assets was 0.88%, down 1.02% year-on-year[2]. - Financial expenses decreased significantly by 929.21% to -3,706,528.56, primarily due to a reduction in interest expenses and an increase in interest income[8]. - Other income increased by 40.36% to 9,035,682.43, mainly attributed to a rise in VAT deductions[8]. - The company reported a credit impairment loss of 552,636.23, a significant turnaround from a loss of -510,785.46 in the previous period[8]. - The company’s diluted earnings per share decreased by 36.20% to 0.1024, reflecting the overall decline in profitability[8]. Acquisitions and Projects - The company completed the acquisition of 100% of Qingdao Yiqing Biotechnology Co., Ltd., enhancing operational efficiency and core competitiveness[13]. - The wastewater resource comprehensive utilization project entered formal production phase after trial operation since April 2023[13]. Accounting and Audit - The company has implemented a new accounting policy effective January 1, 2024, in accordance with the Ministry of Finance of the People's Republic of China, affecting the classification of current and non-current liabilities[22]. - The company did not conduct an audit for the Q3 2024 report, as indicated in the report[23].